Bristol Myers Squibb said on November 3, 2025 it commenced cash tender offers to purchase certain of its outstanding notes for an aggregate purchase price of up to $7 billion.

8-KOther EventsFiled Nov 3, 2025Period of report Nov 3, 2025Summary published (UTC) Oct 12, 2026

Key points

AI summary

Bristol Myers Squibb said on November 3, 2025 it commenced cash tender offers to purchase certain of its outstanding notes for an aggregate purchase price of up to $7 billion.
The company said it set the maximum aggregate purchase price for Pool 1 Notes (Pool 1 Maximum) at $4,000,000,000 and the maximum for Pool 2 Notes (Pool 2 Maximum) at $3,000,000,000, with both maximums excluding applicable Accrued Coupon Payments.
The company set the Early Tender Deadline for November 17, 2025 at 5:00 p.m. (New York City time) and the Expiration Date for December 3, 2025 at 5:00 p.m. (New York City time), and said both may be extended.
The company said it plans to pay the purchase consideration using net proceeds from a New Notes Offering by its subsidiary BMS Ireland Capital Funding Designated Activity Company together with approximately $3.0 billion of Bristol Myers Squibb's cash on hand, and that completion of this financing is a condition to the Offers.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Cash Tender Offers Commenced for Up to $7 billion

Bristol Myers Squibb said on November 3, 2025 it commenced cash tender offers to purchase certain of its outstanding notes for an aggregate purchase price of up to $7 billion.

Source · Based on the filing body and exhibits

Pool 1 and Pool 2 Purchase Price Maximums

The company said it set the maximum aggregate purchase price for Pool 1 Notes (Pool 1 Maximum) at $4,000,000,000 and the maximum for Pool 2 Notes (Pool 2 Maximum) at $3,000,000,000, with both maximums excluding applicable Accrued Coupon Payments.

Source · Based on the filing body and exhibits

Early Tender Deadline and Expiration Date

The company set the Early Tender Deadline for November 17, 2025 at 5:00 p.m. (New York City time) and the Expiration Date for December 3, 2025 at 5:00 p.m. (New York City time), and said both may be extended.

Source · Based on the filing body and exhibits

New Notes Offering and Cash on Hand as Financing Condition

The company said it plans to pay the purchase consideration using net proceeds from a New Notes Offering by its subsidiary BMS Ireland Capital Funding Designated Activity Company together with approximately $3.0 billion of Bristol Myers Squibb's cash on hand, and that completion of this financing is a condition to the Offers.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.